Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $28.00 price target on the stock.
Oculis Holding AG (NASDAQ: OCS) had its price target raised by analysts at Robert W. Baird from $37.00 to $41.00. They now have an "outperform" rating on the stock.
Oculis Holding AG (NASDAQ: OCS) had its price target lowered by analysts at HC Wainwright from $30.00 to $29.00. They now have a "buy" rating on the stock.
Oculis Holding Full Year 2024 Earnings: Misses Expectations [Yahoo! Finance]